Check-Cap Ltd. (NASDAQ:CHEK) reached a new 52-week low on Wednesday . The stock traded as low as $1.24 and last traded at $0.00, with a volume of shares trading hands.

CHEK has been the subject of several research reports. ValuEngine cut Check-Cap from a “hold” rating to a “sell” rating in a research report on Wednesday, July 12th. HC Wainwright set a $6.00 price objective on Check-Cap and gave the company a “buy” rating in a research report on Friday, August 11th. Zacks Investment Research raised Check-Cap from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a research report on Tuesday, October 3rd. Finally, Maxim Group reissued a “buy” rating and issued a $5.00 price objective on shares of Check-Cap in a research report on Wednesday, September 27th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $5.00.

Check-Cap (NASDAQ:CHEK) last issued its earnings results on Thursday, August 10th. The medical research company reported ($0.17) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.01).

A hedge fund recently raised its stake in Check-Cap stock. Sabby Management LLC boosted its position in Check-Cap Ltd. (NASDAQ:CHEK) by 467.9% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,418,893 shares of the medical research company’s stock after purchasing an additional 1,169,061 shares during the quarter. Check-Cap comprises about 0.1% of Sabby Management LLC’s portfolio, making the stock its 24th biggest holding. Sabby Management LLC owned approximately 8.36% of Check-Cap worth $2,724,000 at the end of the most recent reporting period. Institutional investors own 19.29% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Check-Cap Ltd. (CHEK) Sets New 12-Month Low at $1.24” was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at

Check-Cap Company Profile

Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.

Receive News & Ratings for Check-Cap Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.